1. Dashboard

Amgen Inc. NASDAQ: AMGN

Invest Fact Sheet

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience

Name Amgen Inc.
Ticker AMGN
Exchange NASDAQ
Sector Health Care
Industry Biopharmaceuticals
Price 203.50
52W Low/High 166.70 / 243.20
Market cap 120 B
1Y Total Return 10.19%
Above Average
1Y Volatility 22.00%
Less Risk
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience

Details

Ticker AMGN
Name Amgen Inc.
ISIN US0311621009
CUSIP 031162100
Exchange NASDAQ
Sector Health Care
Industry Biopharmaceuticals
Country USA
Currency U.S. Dollar
In Index(ices)
  • US S&P 500 Index
  • Nasdaq 100 Index
  • NASDAQ Biotechnology Index
  • US S&P 100 Index

Share as of 2/27/20

Close Price 203.50
52W Low/High 166.70 / 243.20
Market cap 120 B
1Y Total Return 10.19%
Above Average
1Y Volatility 22.00%
Less Risk
Beta 0.67
PE (trailing) 15.80
Below Average
12M Dividends 5.8
Last Dividend Date 2/13/20
Dividend Yield 2.85%

Fin. Strength

Net Profit Margin 33.6%
Cash from Op. / Cur. Liabilities 0.71
Diluted Earnings / Share 12.88
ROE 70.7%
ROIC 20.8%
Price / Revenue 5.3
Price / Book 12.8
Price / CF 13.5
Current Ratio 1.4
Cur.Liabilities / Tot.Liabilities 0.3
Financial Leverage 3.09
in Mils USD
rolling-year up to December
 
Income Statement 2019 2018 2017 2016 2015 2014  
Revenue
23,362
23,747
22,849
22,991
21,662
20,063
Gross Profit
19,006
19,646
18,780
18,829
17,435
15,641
R&D
4,116
3,737
3,562
3,840
4,070
4,297
EBITDA
12,633
12,883
12,856
12,528
11,181
8,748
Operating Income
9,674
10,263
9,973
9,794
8,470
6,191
Net Income exc. Extra
7,842
8,394
1,979
7,722
6,939
5,158
per Share  
Diluted avg Shares
609
665
735
754
766
770
EPS exc. Extra
12.88
12.62
2.69
10.24
9.06
6.70
Dividend
5.80
5.28
3.45
4.15
3.37
2.62
  
Div. Yield (an.)
2.56%
2.79%
1.96%
2.47%
2.29%
1.68%
  
Balance Sheet 2019 2018 2017 2016 2015 2014  
Total Assets
59,707
66,416
79,954
77,626
71,576
69,009
Cash, Eq & Invt ShortTerm
8,911
29,304
41,678
38,085
31,382
27,026
Total Current Assets
18,440
37,618
49,476
46,010
38,518
34,713
Total Non-Current Assets
41,267
28,798
30,478
31,616
33,058
34,296
Intangibles
34,116
22,142
23,370
25,030
26,428
27,481
Total Liabilities
50,034
53,916
54,713
47,751
43,493
43,231
Total Current Liabilities
12,835
13,488
9,020
11,204
8,667
7,008
Long Term Debt
37,199
40,428
45,693
36,547
34,826
36,223
Shareholder equity
9,673
12,500
25,241
29,875
28,083
25,778
Cash Flow 2019 2018 2017 2016 2015 2014  
Cash from Operations
9,150
11,296
11,177
10,354
9,077
8,555
Depreciation
2,206
1,946
1,955
2,105
2,108
2,092
Cash from Investing
5,709
14,339
-4,024
-8,658
-5,547
-5,752
Capex
618
738
653
660
320
718
Cash from Financing
-15,767
-22,490
-6,594
-2,599
-3,117
-2,877
Stock Issued
-7,702
-17,794
-3,160
-2,910
-1,785
48
Debt (LT) Issued
-4,514
-1,121
71
3,593
1,065
-1,129
Free Cash Flow
8,902
14,673
823
11,780
10,275
6,828
Ratios 2019 2018 2017 2016 2015 2014  
Net Profit Margin
33.6%
35.3%
8.7%
33.6%
32.0%
25.7%
  
NCFO / Op.Income
94.6%
110.1%
112.1%
105.7%
107.2%
138.2%
  
Current Ratio
1.4
2.8
5.5
4.1
4.4
5.0
  
Financial Leverage D/E
3.09
2.71
1.40
1.16
1.12
1.19
  
Return on Capital Avg
20.8%
17.0%
2.8%
14.0%
12.6%
10.9%
  
Return on Shareholder Equity
70.7%
44.5%
7.2%
26.6%
25.8%
21.5%
  

Data

Fundamentals

More Info

No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available